Semaglutide as add-on therapy significantly improved glycemic control and cardiovascular risk markers in T2D patients inadequately controlled on existing medications.
Multi-target improvementAdding semaglutide improved blood sugar, weight, blood pressure, and lipids simultaneously in inadequately controlled diabetes
What the researchers found
Semaglutide add-on therapy improved glycemic control, body weight, blood pressure, and lipid profiles in inadequately controlled T2D patients.
Why it matters
Treatment intensification with the right drug maximizes metabolic and cardiovascular benefit. Semaglutide addresses multiple risk factors simultaneously.
The numbers in context
Two-year follow-up. Measurements at baseline, 12 months (T12), and 24 months (T24). CGM metrics used for glycemic assessment.
How the study worked
Clinical evaluation of semaglutide as add-on to existing diabetes therapy. Assessed HbA1c, weight, cardiovascular risk markers.
Who was studied
Adults with type 1 diabetes on intensive insulin therapy with semaglutide add-on for 2 years
What this study cannot tell us
Study specifics in full paper. Add-on studies may have different baseline characteristics than treatment-naive studies.
How to read the evidence
Moderate evidence: clinical evaluation of semaglutide add-on with multiple metabolic endpoint improvements.
When this study was published
Published in 2025.
The bigger picture
Semaglutide as add-on addresses the growing recognition that diabetes treatment should target multiple cardiometabolic risk factors, not just blood sugar.
Questions still open
- Which baseline therapy combination benefits most from semaglutide addition?
- How quickly do cardiovascular markers improve after adding semaglutide?
- Is semaglutide the optimal add-on for all T2D patients or just certain profiles?
Common questions
Why add semaglutide to my current diabetes medications?
Can I take semaglutide with my current medications?
Read the original research
Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.
Journal of diabetes and its complications, 39(7), 109064
Citation
Al Hayek, Ayman; Klonoff, David C; Al Zahrani, Wael M; Ibrahim, Suzan Eid; Al Dawish, Mohammed A. (2025). Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.. Journal of diabetes and its complications, 39(7), 109064. https://doi.org/10.1016/j.jdiacomp.2025.109064